{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,21]],"date-time":"2026-11-21T02:35:27Z","timestamp":1795228527818,"version":"4.10.3"},"reference-count":80,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:00:00Z","timestamp":1763942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:00:00Z","timestamp":1763942400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000925","name":"Department of Health | National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1137024"],"award-info":[{"award-number":["1137024"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"Department of Health | National Health and Medical Research Council","doi-asserted-by":"publisher","award":["2021"],"award-info":[{"award-number":["2021"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"name":"FightMND, Drug Screening Program FightMND, National Precision Medicine Program Stafford Fox Medical Research Foundation, 2020"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Neurosci"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Heterogeneous and predominantly sporadic neurodegenerative diseases, such as amyotrophic lateral sclerosis (ALS), remain highly challenging to model. Patient-derived induced pluripotent stem cell (iPSC) technologies offer great promise for these diseases; however, large-scale studies demonstrating accelerated neurodegeneration in patients with sporadic disease are limited. Here we generated an iPSC library from 100 patients with sporadic ALS (SALS) and conducted population-wide phenotypic screening. Motor neurons derived from patients with SALS recapitulated key aspects of the disease, including reduced survival, accelerated neurite degeneration correlating with donor survival, transcriptional dysregulation and pharmacological rescue by riluzole. Screening of drugs previously tested in ALS clinical trials revealed that 97% failed to mitigate neurodegeneration, reflecting trial outcomes and validating the SALS model. Combinatorial testing of effective drugs identified baricitinib, memantine and riluzole as a promising therapeutic combination for SALS. These findings demonstrate that patient-derived iPSC models can recapitulate sporadic disease features, paving the way for a new generation of disease modeling and therapeutic discovery in ALS.<\/jats:p>","DOI":"10.1038\/s41593-025-02118-7","type":"journal-article","created":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T10:03:15Z","timestamp":1763978595000},"page":"40-52","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Large-scale drug screening in iPSC-derived motor neurons from sporadic ALS patients identifies a potential combinatorial therapy"],"prefix":"10.1038","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1714-5954","authenticated-orcid":false,"given":"Christopher R.","family":"Bye","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-7323-8112","authenticated-orcid":false,"given":"Elizabeth","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3468-4941","authenticated-orcid":false,"given":"Maciej","family":"Daniszewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fleur C.","family":"Garton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u1ea3o C.","family":"Tr\u1ea7n-L\u00ea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena H.","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3880-4106","authenticated-orcid":false,"given":"John G.","family":"Lock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duncan E.","family":"Crombie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6038-6126","authenticated-orcid":false,"given":"Steven","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0913-4270","authenticated-orcid":false,"given":"Yi","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7601-0238","authenticated-orcid":false,"given":"Samantha K.","family":"Barton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3676-657X","authenticated-orcid":false,"given":"Lucy M.","family":"Palmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7414-6278","authenticated-orcid":false,"given":"Elvan","family":"Djouma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7039-8398","authenticated-orcid":false,"given":"Saritha","family":"Kodikara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim-Anh","family":"L\u00ea Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thanuja","family":"Dharmadasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjali K.","family":"Henders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura A.","family":"Ziser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew C.","family":"Kiernan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5490-1697","authenticated-orcid":false,"given":"Kevin","family":"Talbot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6591-1444","authenticated-orcid":false,"given":"Merrilee","family":"Needham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8632-641X","authenticated-orcid":false,"given":"Susan","family":"Fletcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9866-9068","authenticated-orcid":false,"given":"Paul","family":"Talman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8445-1594","authenticated-orcid":false,"given":"Susan","family":"Mathers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7421-3357","authenticated-orcid":false,"given":"Naomi R.","family":"Wray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5123-5999","authenticated-orcid":false,"given":"Alex W.","family":"Hewitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7408-9453","authenticated-orcid":false,"given":"Alice","family":"Pebay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6580-7655","authenticated-orcid":false,"given":"Bradley J.","family":"Turner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,24]]},"reference":[{"key":"2118_CR1","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1056\/NEJM199403033300901","volume":"330","author":"G Bensimon","year":"1994","unstructured":"Bensimon, G., Lacomblez, L. & Meininger, V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS\/Riluzole Study Group. N. Engl. J. Med. 330, 585\u2013591 (1994).","journal-title":"N. Engl. J. Med."},{"key":"2118_CR2","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1016\/S0140-6736(96)91680-3","volume":"347","author":"L Lacomblez","year":"1996","unstructured":"Lacomblez, L., Bensimon, G., Leigh, P. N., Guillet, P. & Meininger, V. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis\/Riluzole Study Group II. Lancet 347, 1425\u20131431 (1996).","journal-title":"Lancet"},{"key":"2118_CR3","volume":"2012","author":"RG Miller","year":"2012","unstructured":"Miller, R. G., Mitchell, J. D. & Moore, D. H. Riluzole for amyotrophic lateral sclerosis (ALS)\/motor neuron disease (MND). Cochrane Database Syst. Rev. 2012, CD001447 (2012).","journal-title":"Cochrane Database Syst. Rev."},{"key":"2118_CR4","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1056\/NEJMra1603471","volume":"377","author":"RH Brown","year":"2017","unstructured":"Brown, R. H. & Al-Chalabi, A. Amyotrophic lateral sclerosis. N. Engl. J. Med. 377, 162\u2013172 (2017).","journal-title":"N. Engl. J. Med."},{"key":"2118_CR5","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1080\/17482960701856300","volume":"9","author":"S Scott","year":"2008","unstructured":"Scott, S. et al. Design, power, and interpretation of studies in the standard murine model of ALS. Amyotroph. Lateral Scler. 9, 4\u201315 (2008).","journal-title":"Amyotroph. Lateral Scler."},{"key":"2118_CR6","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1002\/med.21661","volume":"40","author":"HJ Wobst","year":"2020","unstructured":"Wobst, H. J., Mack, K. L., Brown, D. G., Brandon, N. J. & Shorter, J. The clinical trial landscape in amyotrophic lateral sclerosis\u2014past, present, and future. Med. Res. Rev. 40, 1352\u20131384 (2020).","journal-title":"Med. Res. Rev."},{"key":"2118_CR7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.nbd.2006.12.015","volume":"26","author":"M Benatar","year":"2007","unstructured":"Benatar, M. Lost in translation: treatment trials in the SOD1 mouse and in human ALS. Neurobiol. Dis. 26, 1\u201313 (2007).","journal-title":"Neurobiol. Dis."},{"key":"2118_CR8","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41582-020-00434-z","volume":"17","author":"MC Kiernan","year":"2021","unstructured":"Kiernan, M. C. et al. Improving clinical trial outcomes in amyotrophic lateral sclerosis. Nat. Rev. Neurol. 17, 104\u2013118 (2021).","journal-title":"Nat. Rev. Neurol."},{"key":"2118_CR9","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41573-022-00612-2","volume":"22","author":"RJ Mead","year":"2023","unstructured":"Mead, R. J., Shan, N., Reiser, H. J., Marshall, F. & Shaw, P. J. Amyotrophic lateral sclerosis: a neurodegenerative disorder poised for successful therapeutic translation. Nat. Rev. Drug Discov. 22, 185\u2013212 (2023).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2118_CR10","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/S1474-4422(13)70036-X","volume":"12","author":"MR Turner","year":"2013","unstructured":"Turner, M. R. et al. Controversies and priorities in amyotrophic lateral sclerosis. Lancet Neurol. 12, 310\u2013322 (2013).","journal-title":"Lancet Neurol."},{"key":"2118_CR11","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1038\/nn.3425","volume":"16","author":"J Sandoe","year":"2013","unstructured":"Sandoe, J. & Eggan, K. Opportunities and challenges of pluripotent stem cell neurodegenerative disease models. Nat. Neurosci. 16, 780\u2013789 (2013).","journal-title":"Nat. Neurosci."},{"key":"2118_CR12","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/nn.4273","volume":"19","author":"S Sances","year":"2016","unstructured":"Sances, S. et al. Modeling ALS with motor neurons derived from human induced pluripotent stem cells. Nat. Neurosci. 19, 542\u2013553 (2016).","journal-title":"Nat. Neurosci."},{"key":"2118_CR13","unstructured":"Talbot, K. et al. Guiding Principles for Drug Discovery and Development in Amyotrophic Lateral Sclerosis (Medicines Discovery Catapult, 2023)."},{"key":"2118_CR14","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.mcn.2013.07.007","volume":"56","author":"MF Burkhardt","year":"2013","unstructured":"Burkhardt, M. F. et al. A cellular model for sporadic ALS using patient-derived induced pluripotent stem cells. Mol. Cell. Neurosci. 56, 355\u2013364 (2013).","journal-title":"Mol. Cell. Neurosci."},{"key":"2118_CR15","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1038\/s41591-018-0140-5","volume":"24","author":"K Fujimori","year":"2018","unstructured":"Fujimori, K. et al. Modeling sporadic ALS in iPSC-derived motor neurons identifies a potential therapeutic agent. Nat. Med. 24, 1579\u20131589 (2018).","journal-title":"Nat. Med."},{"key":"2118_CR16","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/j.cell.2023.01.005","volume":"186","author":"S-T Hung","year":"2023","unstructured":"Hung, S.-T. et al. PIKFYVE inhibition mitigates disease in models of diverse forms of ALS. Cell 186, 786\u2013802 (2023).","journal-title":"Cell"},{"key":"2118_CR17","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.stem.2013.04.003","volume":"12","author":"YM Yang","year":"2013","unstructured":"Yang, Y. M. et al. A small molecule screen in stem-cell-derived motor neurons identifies a kinase inhibitor as a candidate therapeutic for ALS. Cell Stem Cell 12, 713\u2013726 (2013).","journal-title":"Cell Stem Cell"},{"key":"2118_CR18","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaf3962","volume":"9","author":"K Imamura","year":"2017","unstructured":"Imamura, K. et al. The Src\/c-Abl pathway is a potential therapeutic target in amyotrophic lateral sclerosis. Sci. Transl. Med. 9, eaaf3962 (2017).","journal-title":"Sci. Transl. Med."},{"key":"2118_CR19","volume":"35","author":"X Huang","year":"2021","unstructured":"Huang, X. et al. Human amyotrophic lateral sclerosis excitability phenotype screen: target discovery and validation. Cell Rep. 35, 109224 (2021).","journal-title":"Cell Rep."},{"key":"2118_CR20","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-12807-z","volume":"12","author":"E Ustyantseva","year":"2022","unstructured":"Ustyantseva, E. et al. Oxidative stress monitoring in iPSC-derived motor neurons using genetically encoded biosensors of H2O2. Sci. Rep. 12, 8928 (2022).","journal-title":"Sci. Rep."},{"key":"2118_CR21","volume":"4","author":"N Egawa","year":"2012","unstructured":"Egawa, N. et al. Drug screening for ALS using patient-specific induced pluripotent stem cells. Sci. Transl. Med. 4, 145ra104 (2012).","journal-title":"Sci. Transl. Med."},{"key":"2118_CR22","volume":"9","author":"X Sun","year":"2018","unstructured":"Sun, X., Song, J., Huang, H., Chen, H. & Qian, K. Modeling hallmark pathology using motor neurons derived from the family and sporadic amyotrophic lateral sclerosis patient-specific iPS cells. Stem Cell Res. Ther. 9, 315 (2018).","journal-title":"Stem Cell Res. Ther."},{"key":"2118_CR23","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/s41593-021-01006-0","volume":"25","author":"EG Baxi","year":"2022","unstructured":"Baxi, E. G. et al. Answer ALS, a large-scale resource for sporadic and familial ALS combining clinical and multi-omics data from induced pluripotent cell lines. Nat. Neurosci. 25, 226\u2013237 (2022).","journal-title":"Nat. Neurosci."},{"key":"2118_CR24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.celrep.2014.03.019","volume":"7","author":"BJ Wainger","year":"2014","unstructured":"Wainger, B. J. et al. Intrinsic membrane hyperexcitability of amyotrophic lateral sclerosis patient-derived motor neurons. Cell Rep. 7, 1\u201311 (2014).","journal-title":"Cell Rep."},{"key":"2118_CR25","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1016\/j.neuron.2023.01.010","volume":"111","author":"MJ Workman","year":"2023","unstructured":"Workman, M. J. et al. Large-scale differentiation of iPSC-derived motor neurons from ALS and control subjects. Neuron 111, 1191\u20131204 (2023).","journal-title":"Neuron"},{"key":"2118_CR26","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1177\/2472555217696797","volume":"22","author":"DE Crombie","year":"2017","unstructured":"Crombie, D. E. et al. Development of a modular automated system for maintenance and differentiation of adherent human pluripotent stem cells. SLAS Discov. 22, 1016\u20131025 (2017).","journal-title":"SLAS Discov."},{"key":"2118_CR27","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/j.stemcr.2017.03.011","volume":"8","author":"M D\u2019Antonio","year":"2017","unstructured":"D\u2019Antonio, M. et al. High-throughput and cost-effective characterization of induced pluripotent stem cells. Stem Cell Rep. 8, 1101\u20131111 (2017).","journal-title":"Stem Cell Rep."},{"key":"2118_CR28","volume":"6","author":"Z-W Du","year":"2015","unstructured":"Du, Z.-W. et al. Generation and expansion of highly pure motor neuron progenitors from human pluripotent stem cells. Nat. Commun. 6, 6626 (2015).","journal-title":"Nat. Commun."},{"key":"2118_CR29","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/s41593-018-0300-4","volume":"22","author":"JR Klim","year":"2019","unstructured":"Klim, J. R. et al. ALS-implicated protein TDP-43 sustains levels of STMN2, a mediator of motor neuron growth and repair. Nat. Neurosci. 22, 167\u2013179 (2019).","journal-title":"Nat. Neurosci."},{"key":"2118_CR30","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/s41586-022-04436-3","volume":"603","author":"A-L Brown","year":"2022","unstructured":"Brown, A.-L. et al. TDP-43 loss and ALS-risk SNPs drive mis-splicing and depletion of UNC13A. Nature 603, 131\u2013137 (2022).","journal-title":"Nature"},{"key":"2118_CR31","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1038\/s41586-022-04424-7","volume":"603","author":"XR Ma","year":"2022","unstructured":"Ma, X. R. et al. TDP-43 represses cryptic exon inclusion in the FTD\u2013ALS gene UNC13A. Nature 603, 124\u2013130 (2022).","journal-title":"Nature"},{"key":"2118_CR32","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/s41593-022-01205-3","volume":"26","author":"J Humphrey","year":"2023","unstructured":"Humphrey, J. et al. Integrative transcriptomic analysis of the amyotrophic lateral sclerosis spinal cord implicates glial activation and suggests new risk genes. Nat. Neurosci. 26, 150\u2013162 (2023).","journal-title":"Nat. Neurosci."},{"key":"2118_CR33","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1080\/21678421.2017.1407796","volume":"19","author":"MC Hogg","year":"2018","unstructured":"Hogg, M. C., Halang, L., Woods, I., Coughlan, K. S. & Prehn, J. H. M. Riluzole does not improve lifespan or motor function in three ALS mouse models. Amyotroph. Lateral Scler. Frontotemporal Degener. 19, 438\u2013445 (2018).","journal-title":"Amyotroph. Lateral Scler. Frontotemporal Degener."},{"key":"2118_CR34","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/S1474-4422(18)30054-1","volume":"17","author":"T Fang","year":"2018","unstructured":"Fang, T. et al. Stage at which riluzole treatment prolongs survival in patients with amyotrophic lateral sclerosis: a retrospective analysis of data from a dose-ranging study. Lancet Neurol. 17, 416\u2013422 (2018).","journal-title":"Lancet Neurol."},{"key":"2118_CR35","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1093\/brain\/awt085","volume":"136","author":"S Vucic","year":"2013","unstructured":"Vucic, S. et al. Riluzole exerts central and peripheral modulating effects in amyotrophic lateral sclerosis. Brain 136, 1361\u20131370 (2013).","journal-title":"Brain"},{"key":"2118_CR36","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S1474-4422(18)30091-7","volume":"17","author":"T Dharmadasa","year":"2018","unstructured":"Dharmadasa, T. & Kiernan, M. C. Riluzole, disease stage and survival in ALS. Lancet Neurol. 17, 385\u2013386 (2018).","journal-title":"Lancet Neurol."},{"key":"2118_CR37","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1177\/27551938241247778","volume":"54","author":"MB Flynn","year":"2024","unstructured":"Flynn, M. B., Flynn, J. F. & Palacios, A. M. Capitalizing on hope: questionable marketing approval and pricing of a new ALS drug. Int. J. Soc. Determinants Health Health Serv. 54, 405\u2013411 (2024).","journal-title":"Int. J. Soc. Determinants Health Health Serv."},{"key":"2118_CR38","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1001\/jamaneurol.2021.4193","volume":"79","author":"JD Glass","year":"2022","unstructured":"Glass, J. D. & Fournier, C. N. Unintended consequences of approving unproven treatments\u2014hope, hype, or harm? JAMA Neurol. 79, 117\u2013118 (2022).","journal-title":"JAMA Neurol."},{"key":"2118_CR39","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1001\/jamaneurol.2021.4893","volume":"79","author":"S Witzel","year":"2022","unstructured":"Witzel, S. et al. Safety and effectiveness of long-term intravenous administration of edaravone for treatment of patients with amyotrophic lateral sclerosis. JAMA Neurol. 79, 121\u2013130 (2022).","journal-title":"JAMA Neurol."},{"key":"2118_CR40","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abe1923","volume":"13","author":"AN Coyne","year":"2021","unstructured":"Coyne, A. N. et al. Nuclear accumulation of CHMP7 initiates nuclear pore complex injury and subsequent TDP-43 dysfunction in sporadic and familial ALS. Sci. Transl. Med. 13, eabe1923 (2021).","journal-title":"Sci. Transl. Med."},{"key":"2118_CR41","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1038\/s41586-023-06424-7","volume":"620","author":"S Buckberry","year":"2023","unstructured":"Buckberry, S. et al. Transient naive reprogramming corrects hiPS cells functionally and epigenetically. Nature 620, 863\u2013872 (2023).","journal-title":"Nature"},{"key":"2118_CR42","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.brainres.2013.10.013","volume":"1584","author":"T Hatzipetros","year":"2014","unstructured":"Hatzipetros, T. et al. C57BL\/6J congenic Prp-TDP43A315T mice develop progressive neurodegeneration in the myenteric plexus of the colon without exhibiting key features of ALS. Brain Res. 1584, 59\u201372 (2014).","journal-title":"Brain Res."},{"key":"2118_CR43","first-page":"E736","volume":"110","author":"ES Arnold","year":"2013","unstructured":"Arnold, E. S. et al. ALS-linked TDP-43 mutations produce aberrant RNA splicing and adult-onset motor neuron disease without aggregation or loss of nuclear TDP-43. Proc. Natl Acad. Sci. USA 110, E736\u2013E745 (2013).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2118_CR44","doi-asserted-by":"crossref","DOI":"10.1186\/s40478-015-0212-4","volume":"3","author":"JC Mitchell","year":"2015","unstructured":"Mitchell, J. C. et al. Wild type human TDP-43 potentiates ALS-linked mutant TDP-43 driven progressive motor and cortical neuron degeneration with pathological features of ALS. Acta Neuropathol. Commun. 3, 36 (2015).","journal-title":"Acta Neuropathol. Commun."},{"key":"2118_CR45","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.nbd.2010.06.017","volume":"40","author":"NR Stallings","year":"2010","unstructured":"Stallings, N. R., Puttaparthi, K., Luther, C. M., Burns, D. K. & Elliott, J. L. Progressive motor weakness in transgenic mice expressing human TDP-43. Neurobiol. Dis. 40, 404\u2013414 (2010).","journal-title":"Neurobiol. Dis."},{"key":"2118_CR46","doi-asserted-by":"crossref","first-page":"18809","DOI":"10.1073\/pnas.0908767106","volume":"106","author":"I Wegorzewska","year":"2009","unstructured":"Wegorzewska, I., Bell, S., Cairns, N. J., Miller, T. M. & Baloh, R. H. TDP-43 mutant transgenic mice develop features of ALS and frontotemporal lobar degeneration. Proc. Natl Acad. Sci. USA 106, 18809\u201318814 (2009).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2118_CR47","volume":"6","author":"Y-F Xu","year":"2011","unstructured":"Xu, Y.-F. et al. Expression of mutant TDP-43 induces neuronal dysfunction in transgenic mice. Mol. Neurodegener. 6, 73 (2011).","journal-title":"Mol. Neurodegener."},{"key":"2118_CR48","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaz4699","volume":"13","author":"S Rodriguez","year":"2021","unstructured":"Rodriguez, S. et al. Genome-encoded cytoplasmic double-stranded RNAs, found in C9ORF72 ALS\u2013FTD brain, propagate neuronal loss. Sci. Transl. Med. 13, eaaz4699 (2021).","journal-title":"Sci. Transl. Med."},{"key":"2118_CR49","doi-asserted-by":"crossref","DOI":"10.1186\/s40035-023-00380-y","volume":"12","author":"PJ Richardson","year":"2023","unstructured":"Richardson, P. J. et al. Janus kinase inhibitors are potential therapeutics for amyotrophic lateral sclerosis. Transl. Neurodegener. 12, 47 (2023).","journal-title":"Transl. Neurodegener."},{"key":"2118_CR50","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1111\/j.1460-9568.2005.04431.x","volume":"22","author":"R Wang","year":"2005","unstructured":"Wang, R. & Zhang, D. Memantine prolongs survival in an amyotrophic lateral sclerosis mouse model. Eur. J. Neurosci. 22, 2376\u20132380 (2005).","journal-title":"Eur. J. Neurosci."},{"key":"2118_CR51","volume":"12","author":"C Wong","year":"2022","unstructured":"Wong, C. et al. Motor Neuron Disease Systematic Multi-Arm Adaptive Randomised Trial (MND-SMART): a multi-arm, multi-stage, adaptive, platform, phase III randomised, double-blind, placebo-controlled trial of repurposed drugs in motor neuron disease. BMJ Open 12, e064173 (2022).","journal-title":"BMJ Open"},{"key":"2118_CR52","doi-asserted-by":"crossref","first-page":"514","DOI":"10.3109\/17482968.2010.513052","volume":"11","author":"TD Levine","year":"2010","unstructured":"Levine, T. D., Bowser, R., Hank, N. & Saperstein, D. A pilot trial of memantine and riluzole in ALS: correlation to CSF biomarkers. Amyotroph. Lateral Scler. 11, 514\u2013519 (2010).","journal-title":"Amyotroph. Lateral Scler."},{"key":"2118_CR53","doi-asserted-by":"crossref","first-page":"456","DOI":"10.3109\/17482968.2010.498521","volume":"11","author":"M de Carvalho","year":"2010","unstructured":"de Carvalho, M. et al. A randomized, placebo-controlled trial of memantine for functional disability in amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. 11, 456\u2013460 (2010).","journal-title":"Amyotroph. Lateral Scler."},{"key":"2118_CR54","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/S1474-4422(24)00326-0","volume":"23","author":"S Pal","year":"2024","unstructured":"Pal, S. et al. Safety and efficacy of memantine and trazodone versus placebo for motor neuron disease (MND SMART): stage two interim analysis from the first cycle of a phase 3, multiarm, multistage, randomised, adaptive platform trial. Lancet Neurol. 23, 1097\u20131107 (2024).","journal-title":"Lancet Neurol."},{"key":"2118_CR55","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.stem.2016.02.006","volume":"18","author":"T McCaughey","year":"2016","unstructured":"McCaughey, T. et al. An interactive multimedia approach to improving informed consent for induced pluripotent stem cell research. Cell Stem Cell 18, 307\u2013308 (2016).","journal-title":"Cell Stem Cell"},{"key":"2118_CR56","unstructured":"Caetano-Anolles, D. Germline short variant discovery (SNPs\u2009+\u2009indels). GATK https:\/\/gatk.broadinstitute.org\/hc\/en-us\/articles\/360035535932-Germline-short-variant-discovery-SNPs-Indels- (2022)."},{"key":"2118_CR57","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.neuron.2011.09.010","volume":"72","author":"AE Renton","year":"2011","unstructured":"Renton, A. E. et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS\u2013FTD. Neuron 72, 257\u2013268 (2011).","journal-title":"Neuron"},{"key":"2118_CR58","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.neuron.2011.09.011","volume":"72","author":"M DeJesus-Hernandez","year":"2011","unstructured":"DeJesus-Hernandez, M. et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 72, 245\u2013256 (2011).","journal-title":"Neuron"},{"key":"2118_CR59","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s004150170265","volume":"248","author":"G Kuhlenb\u00e4umer","year":"2001","unstructured":"Kuhlenb\u00e4umer, G., Kress, W., Ringelstein, E. B. & St\u00f6gbauer, F. Thirty-seven CAG repeats in the androgen receptor gene in two healthy individuals. J. Neurol. 248, 23\u201326 (2001).","journal-title":"J. Neurol."},{"key":"2118_CR60","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/352077a0","volume":"352","author":"AR La Spada","year":"1991","unstructured":"La Spada, A. R., Wilson, E. M., Lubahn, D. B., Harding, A. E. & Fischbeck, K. H. Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature 352, 77\u201379 (1991).","journal-title":"Nature"},{"key":"2118_CR61","doi-asserted-by":"crossref","first-page":"8043","DOI":"10.1074\/jbc.M112.408211","volume":"288","author":"Y Nihei","year":"2013","unstructured":"Nihei, Y. et al. Enhanced aggregation of androgen receptor in induced pluripotent stem cell-derived neurons from spinal and bulbar muscular atrophy. J. Biol. Chem. 288, 8043\u20138052 (2013).","journal-title":"J. Biol. Chem."},{"key":"2118_CR62","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/nmeth.1591","volume":"8","author":"K Okita","year":"2011","unstructured":"Okita, K. et al. A more efficient method to generate integration-free human iPS cells. Nat. Methods 8, 409\u2013412 (2011).","journal-title":"Nat. Methods"},{"key":"2118_CR63","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.isci.2018.08.016","volume":"7","author":"M Daniszewski","year":"2018","unstructured":"Daniszewski, M. et al. Single-cell profiling identifies key pathways expressed by iPSCs cultured in different commercial media. iScience 7, 30\u201339 (2018).","journal-title":"iScience"},{"key":"2118_CR64","doi-asserted-by":"crossref","DOI":"10.1016\/j.scr.2019.101516","volume":"39","author":"K Bozaoglu","year":"2019","unstructured":"Bozaoglu, K. et al. Generation of seven iPSC lines from peripheral blood mononuclear cells suitable to investigate autism spectrum disorder. Stem Cell Res. 39, 101516 (2019).","journal-title":"Stem Cell Res."},{"key":"2118_CR65","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.cell.2010.12.032","volume":"144","author":"C Bock","year":"2011","unstructured":"Bock, C. et al. Reference maps of human ES and iPS cell variation enable high-throughput characterization of pluripotent cell lines. Cell 144, 439\u2013452 (2011).","journal-title":"Cell"},{"key":"2118_CR66","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1126\/science.282.5391.1145","volume":"282","author":"JA Thomson","year":"1998","unstructured":"Thomson, J. A. et al. Embryonic stem cell lines derived from human blastocysts. Science 282, 1145\u20131147 (1998).","journal-title":"Science"},{"key":"2118_CR67","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/29.9.e45","volume":"29","author":"MW Pfaffl","year":"2001","unstructured":"Pfaffl, M. W. A new mathematical model for relative quantification in real-time RT\u2013PCR. Nucleic Acids Res. 29, e45 (2001).","journal-title":"Nucleic Acids Res."},{"key":"2118_CR68","doi-asserted-by":"publisher","unstructured":"Warnes, G. R. et al. gplots: various R programming tools for plotting data. R Package Version 3.1.3 https:\/\/doi.org\/10.32614\/CRAN.package.gplots (2022).","DOI":"10.32614\/CRAN.package.gplots"},{"key":"2118_CR69","doi-asserted-by":"crossref","unstructured":"Berthold, M. R. et al. KNIME: the Konstanz Information Miner. in Data Analysis, Machine Learning and Applications (eds Preisach, C. et al.) 319\u2013326 (Springer, 2008).","DOI":"10.1007\/978-3-540-78246-9_38"},{"key":"2118_CR70","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.stem.2014.03.004","volume":"14","author":"E Kiskinis","year":"2014","unstructured":"Kiskinis, E. et al. Pathways disrupted in human ALS motor neurons identified through genetic correction of mutant SOD1. Cell Stem Cell 14, 781\u2013795 (2014).","journal-title":"Cell Stem Cell"},{"key":"2118_CR71","unstructured":"R Core Team R: A Language and Environment for Statistical Computing (R Foundation for Statistical Computing, 2021)."},{"key":"2118_CR72","volume":"47","author":"Y Liao","year":"2019","unstructured":"Liao, Y., Smyth, G. K. & Shi, W. The R package Rsubread is easier, faster, cheaper and better for alignment and quantification of RNA sequencing reads. Nucleic Acids Res. 47, e47 (2019).","journal-title":"Nucleic Acids Res."},{"key":"2118_CR73","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1093\/bioinformatics\/btt656","volume":"30","author":"Y Liao","year":"2014","unstructured":"Liao, Y., Smyth, G. K. & Shi, W. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics 30, 923\u2013930 (2014).","journal-title":"Bioinformatics"},{"key":"2118_CR74","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1093\/bioinformatics\/btp616","volume":"26","author":"MD Robinson","year":"2010","unstructured":"Robinson, M. D., McCarthy, D. J. & Smyth, G. K. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26, 139\u2013140 (2010).","journal-title":"Bioinformatics"},{"key":"2118_CR75","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie, M. E. et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43, e47 (2015).","journal-title":"Nucleic Acids Res."},{"key":"2118_CR76","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-023-37266-6","volume":"14","author":"KC Cotto","year":"2023","unstructured":"Cotto, K. C. et al. Integrated analysis of genomic and transcriptomic data for the discovery of splice-associated variants in cancer. Nat. Commun. 14, 1589 (2023).","journal-title":"Nat. Commun."},{"key":"2118_CR77","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41588-017-0004-9","volume":"50","author":"YI Li","year":"2018","unstructured":"Li, Y. I. et al. Annotation-free quantification of RNA splicing using LeafCutter. Nat. Genet. 50, 151\u2013158 (2018).","journal-title":"Nat. Genet."},{"key":"2118_CR78","unstructured":"Pachitariu, M. & Stringer, C. Suite2P: tools for processing 2P recordings. GitHub https:\/\/github.com\/cortex-lab\/Suite2P (2016)."},{"key":"2118_CR79","doi-asserted-by":"publisher","unstructured":"Pachitariu, M. et al. Suite2p: beyond 10,000 neurons with standard two-photon microscopy. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/061507 (2016).","DOI":"10.1101\/061507"},{"key":"2118_CR80","doi-asserted-by":"publisher","unstructured":"Humphrey, J. Gene expression count data from human post-mortem spinal cord. Zenodo https:\/\/doi.org\/10.5281\/zenodo.6385747 (2022).","DOI":"10.5281\/zenodo.6385747"}],"container-title":["Nature Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41593-025-02118-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41593-025-02118-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41593-025-02118-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T14:32:57Z","timestamp":1767796377000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41593-025-02118-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,24]]},"references-count":80,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["2118"],"URL":"https:\/\/doi.org\/10.1038\/s41593-025-02118-7","relation":{},"ISSN":["1097-6256","1546-1726"],"issn-type":[{"value":"1097-6256","type":"print"},{"value":"1546-1726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,24]]},"assertion":[{"value":"25 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare the following competing interests: C.R.B., E.Q., K.L. and B.J.T. are inventors on Australian Provisional Patent Application No. 2024903909 filed by The Florey Institute of Neuroscience and Mental Health for the use of combinations of baricitinib, riluzole and memantine in the treatment of motor neuron disease. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}